Human α-defensin 1 (HNP-1) inhibits adenoviral infection in vitro

Regulatory Peptides

Volumn 101, Issue 1-3, 2001, Pages 157-161

  Bastian, Andreas ^a   Schäfer, Heiner ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Bronchoalveolar lavage; Defense; Gene therapy; Lung

Indexed keywords

ALPHA DEFENSIN 1; BETA DEFENSIN 2; DEFENSIN; IMMUNOGLOBULIN; POLYPEPTIDE; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE TRANSFER; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INFLAMMATORY DISEASE; LUNG INFECTION; LUNG LAVAGE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS INFECTIVITY;

ADENOVIRIDAE; ALPHA-DEFENSINS; ANTIVIRAL AGENTS; BETA-DEFENSINS; BRONCHOALVEOLAR LAVAGE FLUID; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE THERAPY; HUMANS; LUNG DISEASES; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5;

EID: 0035885441     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(01)00282-8     Document Type: Article

References (31)

1. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
2. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration
3. A peptide antibiotic from human skin
4. Defensins promote fusion and lysis of negatively charged membranes
5. Interaction of human defensins with Escherichia coli: Mechanism of bactericidal activity
6. Defensins: Natural peptide antibiotics of human neutrophils
7. Tracheal antimicrobial peptide, a novel cysteine-rich peptide from mammalian tracheal mucosa: Peptide isolation and cloning of a cDNA
8. Direct inactivation of viruses by human granulocyte defensins
9. Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis
10. Production of β-defensins by human airway epithelia
11. Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: Effects on pulmonary epithelium
12. Inhibition of adenovirus-mediated gene transfer by bronchoalveolar lavage
13. Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: A preclinical toxicology study
14. Antibacterial peptides in bronchoalveolar lavage fluid
15. Detection of human alpha-defensin-1, an antimicrobial peptide, in the fluid of jaw cysts
16. The structure of the rabbit macrophage defensin genes and their organ-specific expression
17. Expression of β-defensin genes in bovine alveolar macrophages
18. Activity of defensins from human neutrophilic granulocytes against Mycobacteriumn avium-Mycobacterium intracellulare
19. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelial of patients with cystic fibrosis
20. In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs
21. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
22. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium
23. Safety and efficiency of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats
24. Longterm hepatic adenovirus-mediated gene expression in mice following CTLA41g administration
25. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
26. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice
27. Role of early region E (E3) in pathogenesis of adenovirus disease
28. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer
29. Immunology taught by viruses
30. Generation and analysis of random point mutations in an antibody CDR2 sequence: Many mutated antibodies lose their ability to bind antigen
31. Epithelial defensins impair adenoviral infection: Implication for adenovirus-mediated gene therapy